Yes, Using Budesonide with Dulera is Duplicate Inhaled Corticosteroid Therapy
Using budesonide together with Dulera (mometasone/formoterol) constitutes duplicate inhaled corticosteroid (ICS) therapy and should be avoided unless specifically prescribed as part of a structured regimen. Both medications contain an ICS component—budesonide in one and mometasone in Dulera—which means you would be receiving two separate corticosteroids simultaneously 1.
Why This is Problematic
Dulera Already Contains an ICS
- Dulera is a combination medication containing mometasone furoate (an ICS) and formoterol (a long-acting beta-agonist or LABA) 1.
- The mometasone component provides the anti-inflammatory effect needed for asthma control 1.
- Adding budesonide on top of this creates unnecessary duplication of the corticosteroid component 2.
Risks of Duplicate ICS Therapy
- Increased systemic corticosteroid exposure without additional therapeutic benefit can lead to adverse effects including HPA axis suppression, osteoporosis, glaucoma, and cataracts 1.
- Studies demonstrate that mometasone has approximately 5 times the glucocorticoid receptor binding affinity of budesonide, meaning the mometasone in Dulera is already providing potent anti-inflammatory effects 1.
- The FDA label for Dulera specifically warns about long-term corticosteroid risks and the importance of using the lowest effective dose 1.
Appropriate Asthma Management Strategies
If Asthma is Not Controlled on Dulera Alone
Rather than adding budesonide, consider these evidence-based approaches:
- Increase the Dulera dose if currently on a lower strength (Dulera comes in 50/5,100/5, and 200/5 mcg strengths) 1.
- Verify proper inhaler technique and adherence before intensifying therapy 2.
- Add adjunctive non-ICS therapy such as leukotriene receptor antagonists or consider biologics for severe asthma 2.
The Only Exception: Anti-Inflammatory Reliever Therapy
- The only scenario where using budesonide with Dulera might be appropriate is if budesonide is prescribed as part of an as-needed budesonide/formoterol or budesonide/albuterol reliever regimen 3, 4, 5.
- This represents a specific treatment strategy where budesonide-containing reliever therapy is used on-demand for symptom relief while maintaining regular controller therapy 3, 5.
- However, this would typically involve budesonide combined with a bronchodilator (formoterol or albuterol), not budesonide alone 3, 4.
Key Clinical Pitfalls to Avoid
- Do not assume that "more ICS is better"—combining two ICS medications increases side effect risk without proportional benefit 1.
- Review all prescribed inhalers carefully to identify duplicate therapy, as patients may not recognize that different brand names contain the same drug class 2.
- While using Dulera, do not use other medicines that contain a LABA for any reason, as the FDA label explicitly warns against this duplication 1.
Bottom Line
Discontinue one of the ICS medications. If asthma control is inadequate on Dulera alone, optimize the Dulera dose first or add non-duplicate adjunctive therapy rather than layering another ICS 2, 1. The combination of budesonide with Dulera represents unnecessary duplicate therapy that increases corticosteroid burden without improving outcomes 1.